Meta-Analysis of Infectious Endophthalmitis After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents

被引:166
作者
Fileta, John B. [1 ]
Scott, Ingrid U. [1 ,2 ]
Flynn, Harry W., Jr. [3 ]
机构
[1] Penn State Coll Med, Dept Ophthalmol, Hershey, PA 17033 USA
[2] Penn State Coll Med, Dept Publ Hlth Sci, Hershey, PA 17033 USA
[3] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA
关键词
DIABETIC MACULAR EDEMA; RETINAL VEIN OCCLUSION; VERTEPORFIN PHOTODYNAMIC THERAPY; BEVACIZUMAB AVASTIN INJECTION; ACUTE-ONSET ENDOPHTHALMITIS; FACTOR TRAP-EYE; CHOROIDAL NEOVASCULARIZATION; CAUSATIVE ORGANISMS; PLUS RANIBIZUMAB; CONTROLLED-TRIAL;
D O I
10.3928/23258160-20140306-08
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
BACKGROUND AND OBJECTIVE: To investigate the rate of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents, the spectrum of causative organisms, and associated visual acuity outcomes. PATIENTS AND METHODS: PubMed articles containing the keywords "endophthalmitis'' and "intravitreal'' between January 2005 and May 2012 were identified and reviewed. Inclusion criteria included article in English, more than 100 intravitreal anti-VEGF injections, and report of adverse events including endophthalmitis after intravitreal injection. RESULTS: Forty-three articles were analyzed. Endophthalmitis occurred after 197 of 350,535 intravitreal anti-VEGF injections (0.056%). The most common organisms isolated were coagulase-negative Staphylococcus (38.24%) and Streptococcus species (29.41%). CONCLUSION: The reported rate of endophthalmitis after intravitreal anti-VEGF injection is low. Coagulase-negative Staphylococcus and Streptococcus species were the most frequent causative organisms. Streptococcus species represent the causative organism of endophthalmitis after intravitreal VEGF injections at a higher rate than rates reported in the literature for endophthalmitis following most incisional intraocular surgeries. Among patients with endophthalmitis after intravitreal anti-VEGF injection, endophthalmitis caused by Streptococcus species is associated with poorer visual acuity outcomes than endophthalmitis caused by coagulase-negative Staphylococcus and culture-negative cases.
引用
收藏
页码:143 / 149
页数:7
相关论文
共 58 条
[1]   Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2 [J].
Abraham, Prema ;
Yue, Huibin ;
Wilson, Laura .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2010, 150 (03) :315-324
[2]   Approximate is better than "exact" for interval estimation of binomial proportions [J].
Agresti, A ;
Coull, BA .
AMERICAN STATISTICIAN, 1998, 52 (02) :119-126
[3]  
[Anonymous], SAGE ENCY SOCIAL SCI
[4]   PRIMARY INTRAVITREAL BEVACIZUMAB FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION Results of the Pan-American Collaborative Retina Study Group at 12 Months Follow-up [J].
Arevalo, J. Fernando ;
Fromow-Guerra, Jans ;
Sanchez, Juan G. ;
Maia, Mauricio ;
Berrocal, Maria H. ;
Wu, Lihteh ;
Saravia, Mario J. ;
Costa, Rogerio A. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2008, 28 (10) :1387-1394
[5]   Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection [J].
Artunay, O. ;
Yuzbasioglu, E. ;
Rasier, R. ;
Sengul, A. ;
Bahcecioglu, H. .
EYE, 2009, 23 (12) :2187-2193
[6]   Bilateral Simultaneous Intravitreal Injections in the Office Setting [J].
Bakri, Sophie J. ;
Risco, Miguel ;
Edwards, Albert O. ;
Pulido, Jose S. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2009, 148 (01) :66-69
[7]   Risk of Endophthalmitis After Intravitreal Drug Injection When Topical, Antibiotics Are Not Required The Diabetic Retinopathy Clinical Research Network Laser-Ranibizumab-Triamcinolone Clinical Trials [J].
Bhavsar, Abdhish R. ;
Googe, Joseph M., Jr. ;
Stockdale, Cynthia R. ;
Bressler, Neil M. ;
Brucker, Alexander J. ;
Elman, Michael J. ;
Glassman, Adam R. .
ARCHIVES OF OPHTHALMOLOGY, 2009, 127 (12) :1581-1583
[8]   Vascular Endothelial Growth Factor Trap-Eye for Macular Edema Secondary to Central Retinal Vein Occlusion Six-Month Results of the Phase 3 COPERNICUS Study [J].
Boyer, David ;
Heier, Jeffrey ;
Brown, David M. ;
Clark, W. Lloyd ;
Vitti, Robert ;
Berliner, Alyson J. ;
Groetzbach, Georg ;
Zeitz, Oliver ;
Sandbrink, Rupert ;
Zhu, Xiaoping ;
Beckmann, Karola ;
Haller, Julia A. .
OPHTHALMOLOGY, 2012, 119 (05) :1024-1032
[9]   Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study [J].
Brown, David M. ;
Michels, Mark ;
Kaiser, Peter K. ;
Heier, Jeffrey S. ;
Sy, Judy P. ;
Ianchulev, Tsontcho .
OPHTHALMOLOGY, 2009, 116 (01) :57-65
[10]   Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III Study [J].
Campochiaro, Peter A. ;
Brown, David M. ;
Awh, Carl C. ;
Lee, S. Young ;
Gray, Sarah ;
Saroj, Namrata ;
Murahashi, Wendy Yee ;
Rubio, Roman G. .
OPHTHALMOLOGY, 2011, 118 (10) :2041-2049